Global Large Molecule Drugs CDMO Market Growth (Status and Outlook) 2024-2030

Global Large Molecule Drugs CDMO Market Growth (Status and Outlook) 2024-2030

The global Large Molecule Drugs CDMO market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Large Molecule Drugs CDMO Industry Forecast” looks at past sales and reviews total world Large Molecule Drugs CDMO sales in 2023, providing a comprehensive analysis by region and market sector of projected Large Molecule Drugs CDMO sales for 2024 through 2030. With Large Molecule Drugs CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Large Molecule Drugs CDMO industry.

This Insight Report provides a comprehensive analysis of the global Large Molecule Drugs CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Large Molecule Drugs CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Large Molecule Drugs CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Large Molecule Drugs CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Large Molecule Drugs CDMO.

United States market for Large Molecule Drugs CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Large Molecule Drugs CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Large Molecule Drugs CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Large Molecule Drugs CDMO players cover Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc. and Rentschler Biopharma SE, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Large Molecule Drugs CDMO market by product type, application, key players and key regions and countries.

Segmentation by type
Cell Line Development
Large Molecule Drug Substance Development

Segmentation by application
Biological Technology
Clinical
Pharmaceutical
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific

Please note: The report will take approximately 2 business days to prepare and deliver.